APA (7th ed.) Citation

Olagunju, A., Fowotade, A., Olagunoye, A., Ojo, T. O., Adefuye, B. O., Fagbamigbe, A. F., . . . Owen, A. (2021). Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID). Trials, 22(1), . https://doi.org/10.1186/s13063-020-04987-8

Chicago Style (17th ed.) Citation

Olagunju, Adeniyi, et al. "Efficacy and Safety of Nitazoxanide Plus Atazanavir/ritonavir for the Treatment of Moderate to Severe COVID-19 (NACOVID)." Trials 22, no. 1 (2021). https://doi.org/10.1186/s13063-020-04987-8.

MLA (9th ed.) Citation

Olagunju, Adeniyi, et al. "Efficacy and Safety of Nitazoxanide Plus Atazanavir/ritonavir for the Treatment of Moderate to Severe COVID-19 (NACOVID)." Trials, vol. 22, no. 1, 2021, https://doi.org/10.1186/s13063-020-04987-8.